PTHS - Channel Therapeutics Corp Price-to-Projected Revenue Ratio

Channel Therapeutics focuses on developing myelin regeneration methods, avoiding price wars through its scientific uniqueness. The company's forward P/S trend reflects market expectations, while the 0.70 metric confirms the current level. A team of leading neurobiologists operates in state-of-the-art laboratories with full academic freedom. Success is accelerating through strategic alliances with scientific centers to study ion channels.

Channel Therapeutics Inc. - PTHS Projected Price to Revenue (period 07/03/2025 - 11/13/2026)

Summary analytical data breakdowns for Channel Pharma (PTHS)

- market price and analyst price targets:

Price Chart Channel Therapeutics Corp|PTHS - Price Target Chart

- market capitalization statistics:

Market Value Channel Pharma|PTHS - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Channel Therapeutics|PTHS - Book Value of Business|Market Cap to Net Assets Ratio channeltherapeutics.com|PTHS - Company Assets

- debt and liquidity data:

- financial results and valuation multiples details:

PTHS - Company Profit|Projected Future Earnings Channel Therapeutics|PTHS - Market Cap to Earnings|Future Price to Earnings Channel|PTHS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Channel Pharma|PTHS - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Channel Therapeutics|PTHS - Earnings per share for the last four quarters|Quarterly EPS earnings growth channeltherapeutics.com|PTHS - Earnings per share increase in current year|Earnings growth forecast for next year Channel Therapeutics

- revenue and sales proceeds data:

PTHS - Company Total Revenue|Company Projected Revenue Channel Therapeutics Corp|PTHS - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Channel Pharma

Summary company analysis:Channel Therapeutics Corp PTHS

For Channel Therapeutics (PTHS), the forward P/S ratio serves as a gauge of market expectations regarding the future monetization of innovative drugs for the treatment of ion channel pathologies. By comparing current market capitalization with expected revenues, the forward P/S trend allows for an assessment of the expansion potential into neuropharmacology already priced in; while steady growth of the indicator confirms investment attractiveness, a sharp peak signals an overvaluation of the asset.

Competitors of Channel Therapeutics

Price-to-Projected Revenue Ratio Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scholar Rock Inc.|CNTA: Forward P/S Multiple|Projected Price to Revenue dyne-tx.com DYN|Forward Price-to-Revenue Multiple EWTX|Market Cap to Future Revenue Ratio Rapport Therapeutics Inc RAPP|Forward P/S Multiple ALMS|Forward Price-to-Revenue Multiple Zevra Corp ZVRA|Forward P/S Multiple CTNM (Contineum Therapeutics, Inc.)|Forward Price to Sales LRMR|Capricor - Forward P/S Multiple|TRDA - Forward P/S Multiple|medicinova.com (MNOV) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SER|Price-to-Projected Revenue Ratio BioXcel Therapeutics|Market Cap to Projected Revenue PMN (ProMIS)|Forward P/S Multiple APUS|AEON - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio NLS Pharmaceutics NLSP|Bionomics Ltd. - Price-to-Projected Revenue Ratio|HUGE: Forward Price-to-Revenue Multiple|Forward Price to Sales RETA (reatapharma.com)